CCNA 影像工作组关于阿尔茨海默病改变疗法背景下的影像建议。

IF 2.9 4区 医学 Q2 CLINICAL NEUROLOGY Canadian Journal of Neurological Sciences Pub Date : 2024-11-04 DOI:10.1017/cjn.2024.338
Simon Duchesne, D Louis Collins, Laura Barlow, Robert Bartha, Sandra Black, Howard Chertkow, Mahsa Dadar, Manish Joshi, Pedro Rosa-Neto, Jean-Paul Soucy, Eric E Smith
{"title":"CCNA 影像工作组关于阿尔茨海默病改变疗法背景下的影像建议。","authors":"Simon Duchesne, D Louis Collins, Laura Barlow, Robert Bartha, Sandra Black, Howard Chertkow, Mahsa Dadar, Manish Joshi, Pedro Rosa-Neto, Jean-Paul Soucy, Eric E Smith","doi":"10.1017/cjn.2024.338","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Disease-modifying therapies (DMTs) for Alzheimer's disease (AD) are emerging following successful clinical trials of therapies targeting amyloid beta (Aβ) protofibrils or plaques. Determining patient eligibility and monitoring treatment efficacy and adverse events, such as Aβ-related imaging abnormalities, necessitates imaging with MRI and PET. The Canadian Consortium on Neurodegeneration in Aging (CCNA) Imaging Workgroup aimed to synthesize evidence and provide recommendations on implementing imaging protocols for AD DMTs in Canada.</p><p><strong>Methods: </strong>The workgroup employed a Delphi process to develop these recommendations. Experts from radiology, neurology, biomedical engineering, nuclear medicine, MRI and medical physics were recruited. Surveys and meetings were conducted to achieve consensus on key issues, including protocol standardization, scanner strength, monitoring protocols based on risk profiles and optimal protocol lengths. Draft recommendations were refined through multiple iterations and expert discussions.</p><p><strong>Results: </strong>The recommendations emphasize standardized acquisition imaging protocols across manufacturers and scanner strengths to ensure consistency and reliability of clinical treatment decisions, tailored monitoring protocols based on DMTs' safety and efficacy profiles, consistent monitoring regardless of perceived treatment efficacy and MRI screening on 1.5T or 3T scanners with adapted protocols. An optimal protocol length of 20-30 minutes was deemed feasible; specific sequences are suggested.</p><p><strong>Conclusion: </strong>The guidelines aim to enhance imaging data quality and consistency, facilitating better clinical decision-making and improving patient outcomes. Further research is needed to refine these protocols and address evolving challenges with new DMTs. It is recognized that administrative, financial and logistical capacity to deliver additional MRI and positron emission tomography scans require careful planning.</p>","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"1-9"},"PeriodicalIF":2.9000,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Recommendations on Imaging in the Context of Alzheimer's Disease-Modifying Therapies from the CCNA Imaging Workgroup.\",\"authors\":\"Simon Duchesne, D Louis Collins, Laura Barlow, Robert Bartha, Sandra Black, Howard Chertkow, Mahsa Dadar, Manish Joshi, Pedro Rosa-Neto, Jean-Paul Soucy, Eric E Smith\",\"doi\":\"10.1017/cjn.2024.338\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Disease-modifying therapies (DMTs) for Alzheimer's disease (AD) are emerging following successful clinical trials of therapies targeting amyloid beta (Aβ) protofibrils or plaques. Determining patient eligibility and monitoring treatment efficacy and adverse events, such as Aβ-related imaging abnormalities, necessitates imaging with MRI and PET. The Canadian Consortium on Neurodegeneration in Aging (CCNA) Imaging Workgroup aimed to synthesize evidence and provide recommendations on implementing imaging protocols for AD DMTs in Canada.</p><p><strong>Methods: </strong>The workgroup employed a Delphi process to develop these recommendations. Experts from radiology, neurology, biomedical engineering, nuclear medicine, MRI and medical physics were recruited. Surveys and meetings were conducted to achieve consensus on key issues, including protocol standardization, scanner strength, monitoring protocols based on risk profiles and optimal protocol lengths. Draft recommendations were refined through multiple iterations and expert discussions.</p><p><strong>Results: </strong>The recommendations emphasize standardized acquisition imaging protocols across manufacturers and scanner strengths to ensure consistency and reliability of clinical treatment decisions, tailored monitoring protocols based on DMTs' safety and efficacy profiles, consistent monitoring regardless of perceived treatment efficacy and MRI screening on 1.5T or 3T scanners with adapted protocols. An optimal protocol length of 20-30 minutes was deemed feasible; specific sequences are suggested.</p><p><strong>Conclusion: </strong>The guidelines aim to enhance imaging data quality and consistency, facilitating better clinical decision-making and improving patient outcomes. Further research is needed to refine these protocols and address evolving challenges with new DMTs. It is recognized that administrative, financial and logistical capacity to deliver additional MRI and positron emission tomography scans require careful planning.</p>\",\"PeriodicalId\":56134,\"journal\":{\"name\":\"Canadian Journal of Neurological Sciences\",\"volume\":\" \",\"pages\":\"1-9\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-11-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Canadian Journal of Neurological Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1017/cjn.2024.338\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Neurological Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/cjn.2024.338","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:在针对β淀粉样蛋白(Aβ)原原纤维或斑块的治疗成功的临床试验之后,阿尔茨海默病(AD)的疾病修饰疗法(DMTs)正在出现。确定患者的资格,监测治疗效果和不良事件,如a β相关的影像学异常,需要MRI和PET成像。加拿大老年神经退行性变(CCNA)成像工作组旨在综合证据并为加拿大AD dmt的成像方案提供建议。方法:工作组采用德尔菲法制定这些建议。招募了来自放射学、神经学、生物医学工程、核医学、核磁共振成像和医学物理学的专家。进行了调查和会议,以就关键问题达成共识,包括协议标准化、扫描仪强度、基于风险概况的监测协议和最佳协议长度。通过多次迭代和专家讨论,建议草案得到了完善。结果:这些建议强调了跨制造商和扫描仪优势的标准化采集成像方案,以确保临床治疗决策的一致性和可靠性,根据dmt的安全性和有效性概况量身定制的监测方案,不考虑感知治疗效果的一致性监测以及采用适应方案的1.5T或3T扫描仪的MRI筛查。最佳协议长度为20-30分钟是可行的;提出了具体的顺序。结论:该指南旨在提高影像数据的质量和一致性,促进临床决策,改善患者预后。需要进一步的研究来完善这些协议,并通过新的dmt解决不断变化的挑战。人们认识到,提供额外核磁共振成像和正电子发射断层扫描的行政、财政和后勤能力需要仔细规划。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Recommendations on Imaging in the Context of Alzheimer's Disease-Modifying Therapies from the CCNA Imaging Workgroup.

Background: Disease-modifying therapies (DMTs) for Alzheimer's disease (AD) are emerging following successful clinical trials of therapies targeting amyloid beta (Aβ) protofibrils or plaques. Determining patient eligibility and monitoring treatment efficacy and adverse events, such as Aβ-related imaging abnormalities, necessitates imaging with MRI and PET. The Canadian Consortium on Neurodegeneration in Aging (CCNA) Imaging Workgroup aimed to synthesize evidence and provide recommendations on implementing imaging protocols for AD DMTs in Canada.

Methods: The workgroup employed a Delphi process to develop these recommendations. Experts from radiology, neurology, biomedical engineering, nuclear medicine, MRI and medical physics were recruited. Surveys and meetings were conducted to achieve consensus on key issues, including protocol standardization, scanner strength, monitoring protocols based on risk profiles and optimal protocol lengths. Draft recommendations were refined through multiple iterations and expert discussions.

Results: The recommendations emphasize standardized acquisition imaging protocols across manufacturers and scanner strengths to ensure consistency and reliability of clinical treatment decisions, tailored monitoring protocols based on DMTs' safety and efficacy profiles, consistent monitoring regardless of perceived treatment efficacy and MRI screening on 1.5T or 3T scanners with adapted protocols. An optimal protocol length of 20-30 minutes was deemed feasible; specific sequences are suggested.

Conclusion: The guidelines aim to enhance imaging data quality and consistency, facilitating better clinical decision-making and improving patient outcomes. Further research is needed to refine these protocols and address evolving challenges with new DMTs. It is recognized that administrative, financial and logistical capacity to deliver additional MRI and positron emission tomography scans require careful planning.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.30
自引率
3.30%
发文量
330
审稿时长
4-8 weeks
期刊介绍: Canadian Neurological Sciences Federation The Canadian Journal of Neurological Sciences is the official publication of the four member societies of the Canadian Neurological Sciences Federation -- Canadian Neurological Society (CNS), Canadian Association of Child Neurology (CACN), Canadian Neurosurgical Society (CNSS), Canadian Society of Clinical Neurophysiologists (CSCN). The Journal is a widely circulated internationally recognized medical journal that publishes peer-reviewed articles. The Journal is published in January, March, May, July, September, and November in an online only format. The first Canadian Journal of Neurological Sciences (the Journal) was published in 1974 in Winnipeg. In 1981, the Journal became the official publication of the member societies of the CNSF.
期刊最新文献
Access to Endovascular Thrombectomy: Does Driving Time to Comprehensive Stroke Center Matter More than Rurality? Creation and evolution of the Ontario Stroke Registry: protocol and two decades of data from a population-based clinical stroke registry. Improving Epilepsy Care in Ontario, Canada: the Impact of a Provincial Strategy for Epilepsy Care. Deep Brain Stimulation for Substance Use Disorder: Case Report of Fentanyl Use Disorder and Review of the Literature. Safety of Dabigatran in Acute Ischemic Stroke Patients with Microbleeds: Post hoc Analysis of DATAS-II Randomized Trial.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1